Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

eUpdate – Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations  

Published: 01 April 2020. Authors: ESMO Guidelines Committee

Clinical Practice Guidelines

This update refers to Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ledermann JA, Raja FA, Fotopoulou C et al. Ann Oncol 2013; 24 (Suppl 6): vi24–vi32.

Section

Chemotherapy in recurrent ovarian cancer, Targeted therapy

Text update

Following the results of the first randomised maintenance trial with olaparib demonstrating a significant improvement in progression-free survival (PFS), particularly in patients with a BRCA mutation [1], further data has emerged and three other phase III trials with other poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have been conducted [2-4]. Maintenance therapy after platinum-based chemotherapy (ChT) for recurrent ovarian cancer with niraparib, rucaparib or olaparib (tablet formulation) has a wider clinical benefit. A PFS benefit is seen with all three drugs, not only in tumours with a BRCA mutation [germline (gBRCA)] or somatic (sBRCA)] but also in BRCA wild-type tumours. The greatest improvement in PFS is seen in BRCA-mutated tumours; with PFS hazard ratios (HR) of 0.27 [95% confidence interval (CI) 0.17–0.41] median PFS 21.0 versus 5.5 months for niraparib in gBRCA patients [3]; HR 0.23 (95% CI 0.16–0.34) with a median PFS of 16.0 versus 5.4 months for rucaparib in tumour BRCA-positive (tBRCA) patients [2]; and HR 0.30 (95% CI 0.22–0.41) median PFS 19.1 versus 5.5 months for olaparib in tBRCA (combined gBRCA and sBRCA) patients [4]. A significant but lesser benefit is seen in tumours testing positive by commercial HRD (homologous recombination deficient repair of DNA) assays but the significant PFS in HRD-negative patients, and ‘all comer’ analyses has led to European Medicines Agency (EMA) approval of all three PARP inhibitors as maintenance therapy in high-grade ovarian cancers irrespective of their BRCA status. For niraparib, in the non-g BRCA group that includes sBRCA patients, the HR is 0.45 (95% CI 0.34–0.61) with a median PFS of 9.3 versus 3.9 months [3]. For rucaparib, in the intention to treat population, the HR is 0.36 (95% CI 0.30–0.45) with a median PFS of 10.8 versus 5.4 months [2]. The olaparib tablet approval for non BRCA-mutated tumours is based on the subgroup analysis of Study 19 with a HR 0.54 (95% CI 0.34-0.85) and a median PFS of 7.4 versus 5.5 months [1]. Data are not yet mature for overall survival apart from the first study (Study 19) where a non-significant prolongation in survival, HR 0.73 (95% CI 0.55‒0.95) was seen for patients on olaparib. In this study, 11% patients (in BRCA-mutated and BRCA wild type groups) remaining on treatment for >6 years without disease progression [5].

Overall, maintenance therapy with a PARP inhibitor following platinum-based ChT is a new standard of care option in patients who do not require ChT with bevacizumab [6]. The EMA has also approved rucaparib monotherapy for patients with a germline or somatic BRCA mutation who have received at least two lines of therapy and are unable to receive platinum-based treatment. This was based on a combined analysis of two phase II trials, ARIEL2 and Study 10, demonstrating a response rate of 53.8% (95% CI 43.8–63.5) with 8.5% and 45.3% of patients achieving a complete and partial responses, respectively. The median duration of response was 9.2 months (95% CI 6.6–11.6) [7].

Recommendations

  • Maintenance therapy with a PARP inhibitor (olaparib, niraparib or rucaparib) following a response to platinum-based therapy in patients with recurrent platinum-sensitive high-grade ovarian cancer is a new standard of care option, irrespective of BRCA status [I, A].
  • For patients with recurrent platinum-sensitive ovarian cancer and a BRCA mutation unable to receive platinum-based therapy, rucaparib monotherapy is an option [III, A].

References

  1. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–861.
  2. Coleman RL, Oza AM, Lorusso D et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 1949–1961.
  3. Mirza MR, Monk BJ, Herrstedt J et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375: 2154–2164.
  4. Pujade-Lauraine E, Ledermann JA, Selle F et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1274–1284.
  5. Friedlander M, Matulonis U, Gourley C et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018; 119: 1075–1085.
  6. Colombo N, Sessa C, du Bois A et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019; 30: 672–705.
  7. Oza AM, Tinker AV, Oaknin A et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 2017; 147: 267–275.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings